Hsp-based tumor vaccines: state-of-the-art and future directions

Hsp-based tumor vaccines, autologous tumor-derived Hsp-peptide complexes, have been applied to cancer immunotherapy for the treatment of cancer patients with a variety of advanced malignancies. Data from clinical trials, including those from phase III, have so far demonstrated that the immunization...

Full description

Saved in:
Bibliographic Details
Published inCurrent opinion in molecular therapeutics Vol. 9; no. 4; p. 385
Main Authors Takakura, Yoshinobu, Takemoto, Seiji, Nishikawa, Makiya
Format Journal Article
LanguageEnglish
Published England 01.08.2007
Subjects
Adenoviridae - genetics
Adenoviridae - metabolism
Cancer Vaccines - therapeutic use
Genetic Vectors - genetics
Genetic Vectors - metabolism
Heat-Shock Proteins - genetics
Heat-Shock Proteins - immunology
Heat-Shock Proteins - therapeutic use
Humans
Immunotherapy, Active - trends
Recombinant Fusion Proteins - genetics
Recombinant Fusion Proteins - therapeutic use
Vaccines, DNA - therapeutic use
Online AccessGet more information
ISSN1464-8431

Cover

More Information
Summary:Hsp-based tumor vaccines, autologous tumor-derived Hsp-peptide complexes, have been applied to cancer immunotherapy for the treatment of cancer patients with a variety of advanced malignancies. Data from clinical trials, including those from phase III, have so far demonstrated that the immunization strategy can induce significant tumor-specific immune responses. Some improved clinical outcomes have also been observed but the clinical utility of this strategy awaits further investigations. In addition, preclinical studies have been conducted to design a variety of novel Hsp-based tumor vaccines with improved therapeutic potentials. These approaches include development of Hsp fusion proteins and genetic vaccines using plasmid DNA and adenoviruses. Successful cancer immunotherapy with Hsp-based tumor vaccines will depend on the results obtained from both clinical trials and preclinical studies.
ISSN:1464-8431